Monday, May 26
Lawrence Business Magazine LLC
Lawrence Business Magazine LLC
2014 Fourth Quarter - New & Growing Technology

CritiTech & Deciphera

By on 99 Comments
INNOVATION: DEVELOPING NEW DRUGS AND NEW DRUG DELIVERY SYSTEMS IN LAWRENCE
| 2014 Q4 | story by LIZ WESLANDER    | photos by STEVEN HERTZOG |
Tech

Deciphera lab

Hidden in plain sight among unassuming buildings in downtown and north Lawrence are two high-tech biotechnology companies that are working on innovative cancer treatments that could be available on the market in the future.

CritiTech, a Lawrence born-and-bred drug development company, operates both its labs and business offices in a space along E. 1450 Rd just north of downtown. Deciphera, with its business headquarters in Boston, Mass. has biology and chemistry labs located on the 600 block of Massachusetts Street- right across from the Free State Brewery.

Daniel Flynn, the CSO and Founder of Deciphera Pharmaceuticals, received his Ph.D. in medicinal chemistry at the University of Kansas. Flynn said that when he established Deciphera in 2003, he could have located the company’s research labs anywhere in the country. He chose Lawrence.

Tech

CritiTech lab equipment

“I wasn’t wooed here, I came voluntarily.” Flynn said. “Even back 10 years ago there was a beginning of a desire from the thought leaders of the city wanting to bring Lawrence forward as a regional biotech hub. I wanted to be a part of that.”

Deciphera’s labs were originally located at KU’s Life Science Research Laboratories, at 1501 Wakarusa. In 2011, they moved to their downtown location.

“It’s surprising that we would have a research lab above Chico’s and the Gap, but we worked with city commission to make them comfortable with being us downtown,” Flynn said. “Lawrence is a wonderful town to work in. At least a third of our hires have been KU graduates or KU-affiliated. We have had no problem tapping into the human resources that have been available here.”

Deciphera specializes in developing cancer-fighting pharmaceuticals that use a technology called kinase inhibitors. Kinases are enzymes that transmit signals within cells to help the cells function. Kinase have “switch” mechanisms that allow the enzymes to “turn on” to perform its function, and “turn off” when not needed. Mutations in a kinase switch can cause a kinase to remain on continually, which can cause a cell to become cancerous. Kinase inhibitors work by targeting the faulty kinase switch, which cuts off the ability of tumor cells to thrive and spread.

“Our approach to cancer is not the standard chemotherapy, which is designed to kill any cell whether it is cancer or not,” Flynn said. “Kinase inhibiters are targeted therapeutics – they go into a cell and target the runaway kinase. The side-effect profile is much more favorable this way.”

Flynn said that Deciphera has spent the past five to six years focusing on researching and developing its specialized kinase inhibitor technology platform to produce drug candidates. It now has five drug candidates at various stages development that utilize the company’s technology. The ultimate goal is to advance these candidates into human clinical trials so that they may ultimately be available on the market to treat cancer patients. Clinical trials measure outcomes and assess the safety and effectiveness of a new drug or combination of drugs. New pharmaceuticals undergo three phases of clinical trials before being approved for marketing. Deciphera currently has three drug candidates in Phase I clinical trials, including one that is being developed in partnership with pharmaceutical giant Eli Lily.

Tech

Dechipera, front row left to right: Cynthia Leary, Anjanette Wilhelm & Daniel Flynn. Back row: Mike Kauffman, Bryan Smith, Linda Martin, Susan McElwain & John Lord

Flynn said that partnering with Eli Lily in the early stages of clinical trials was in Deciphera’s best interest for this particular drug. However, the company plans to conduct Phase I trials for its other drug platforms in its Lawrence labs when possible. It will then seek strategic partnerships with pharmaceutical companies once the drugs have advanced to later phases.

“Our design is to finish Phase I clinical trials in-house,” Flynn said. “It is all about risk and reward. If we have internal phase-one data that looks good, that leads to more favorable partnerships in the future.”

Deciphera recently hired Mike Taylor, a veteran of the bioscience deal-making industry, to serve as its new president and CEO. Taylor communes between Lawrence and Boston offices.

“It’s great to have him on board,” Flynn said. “He brings a good business acumen to the company.”

Deciphera currently has 16 total employees between the Lawrence and Boston offices. Although the company is currently focusing its attention on a few of its drug platforms, Flynn said that Deciphera has no shortage of other drugs with the potential to advance into clinical trials.

“We have a backlog of assets,” Flynn said. “Most companies our size have one or two assets, and they live or die based on those. We have a wealth of riches in our war chest.”

Where Deciphera uses its technology to create new drug formulations to fight cancer, CritiTech specializes in reformulating and improving pharmaceuticals that are already on the market. CritiTech is currently working on a reformulated version of the widely administered chemotherapy drug, Paclitaxel. The reformulated drug, which CritiTech has named Nanotax, performed favorably in a recent Phase I clinical trial focusing on ovarian cancer patients at the KU Medical Center.

CritiTech reformulates existing drugs using proprietary technology that transforms existing drug formulations into very fine particles. The core base of CritiTech’s technology was developed at KU by researcher, Bala Subramaniam, and CritiTech has continued to evolve and expand this technology, according to CritiTech President Matthew McClorey. Reformulating existing drugs into smaller particles can have a number of benefits, including making drugs less toxic, more effective and easier to administer.

Tech

President of CritiTech Matthew McClorey

McClorey said that CritiTech’s reformulation of Paclitaxel into Nanotax is an ideal example of what can be done with CritiTech’s technology. Paclitaxel is currently administered to ovarian cancer patients intravenously using a toxic delivery agent called Cremaphor. By reformulating Paclitaxel into smaller particles using its technology, CritiTech’s reformulated version, Nanotax, can be administered straight into the abdomen using water or saline.

“This is important because the Cremaphor creates significant toxicity for the patients. And because the Paclitaxel is administered into the vein, those toxic effects are systemic,” McClorey said. “The results of Nanotax Phase I trial indicated that it can be delivered at the site of the tumor, in a higher concentration, for a longer period of time, and without the typical side effects and toxicity that is associated with the drug that is currently on the market.”

McClorey said that CritiTech plans to move Nanotax forward in advanced clinical trials, and hopes the drug will be on the market in a few years. He also said that there is a good possibility that Nanotax will be applicable to other cancers including breast, liver and colorectal.

“We think we can improve the lives of ovarian cancer patients with this drug,” McClorey said. “We need to do expanded trials to prove that out, but that is why we are doing what we are doing – to improve the quality of life for these women and hopefully help them to live longer.”

With a solid example of what CritiTech’s technology can do well under way, the company is now starting to offer the technology’s service to other drug companies. Just as CritiTech developed a new and improved version of Paclitaxel, it wants to help other pharmaceutical companies.

“We have started providing this third-party drug development in this past year,” McClorey said. “We have had some contracts coming in from companies that are exploring the use of our technology as applied to the compounds that they are developing. Just like we developed a new and improved version of Paclitaxel, we want to help other pharmaceutical companies develop a new and improved version of their products.”

Share.

Related Posts

99 Comments

  2. gamdom giriş on

    Hello! I could have sworn I’ve been to this site before but after browsing through a few of the articles I realized it’s new to me. Regardless, I’m definitely happy I came across it and I’ll be book-marking it and checking back frequently!

  3. gamdom giriş on

    I’m very happy to uncover this website. I want to to thank you for ones time due to this wonderful read!! I definitely really liked every little bit of it and I have you saved as a favorite to look at new things on your website.

  7. Hire A Killer on

    Howdy! I know this is somewhat off topic but I was wondering which blog platform are you using for this website? I’m getting fed up of WordPress because I’ve had issues with hackers and I’m looking at options for another platform. I would be fantastic if you could point me in the direction of a good platform.|

  16. Hire A Killer on

    Greetings! Very helpful advice in this particular article! It’s the little changes which will make the biggest changes. Thanks a lot for sharing!|

  25. gamdom giriş on

    What i don’t realize is actually how you’re not really much more well-liked than you may be right now. You are very intelligent. You realize thus considerably relating to this subject, made me personally consider it from a lot of varied angles. Its like women and men aren’t fascinated unless it?s one thing to accomplish with Lady gaga! Your own stuffs excellent. Always maintain it up!

  34. gamdom giriş on

    Thanks for the suggestions you have shared here. Furthermore, I believe there are many factors that will keep your car insurance policy premium down. One is, to contemplate buying vehicles that are inside the good set of car insurance providers. Cars which can be expensive tend to be at risk of being lost. Aside from that insurance is also using the value of your truck, so the more costly it is, then higher a premium you only pay.

  37. สาวน่าเย็ด on

    Right here is the right webpage for everyone who wishes to understand this topic. You realize so much its almost tough to argue with you (not that I really will need to…HaHa). You certainly put a new spin on a subject which has been discussed for years. Excellent stuff, just great.

  39. 에볼루션카지노 on

    Thanks for the concepts you have contributed here. Furthermore, I believe there are several factors that really keep your auto insurance premium straight down. One is, to contemplate buying cars that are inside good directory of car insurance companies. Cars which have been expensive are usually more at risk of being snatched. Aside from that insurance coverage is also in line with the value of your truck, so the more pricey it is, then the higher a premium you only pay.

  42. อิงฟ้า xxx on

    May I simply say what a comfort to uncover somebody who truly understands what they’re talking about on the web. You definitely realize how to bring a problem to light and make it important. More people ought to look at this and understand this side of the story. I was surprised you aren’t more popular since you surely have the gift.

  45. 라이브카지노 on

    I do consider all of the ideas you have offered in your post. They are really convincing and will definitely work. Still, the posts are too brief for starters. May just you please lengthen them a little from next time? Thanks for the post.

  46. หนังโป้มด on

    Next time I read a blog, Hopefully it does not disappoint me as much as this particular one. I mean, Yes, it was my choice to read through, nonetheless I truly believed you’d have something helpful to say. All I hear is a bunch of moaning about something you could possibly fix if you were not too busy looking for attention.

  51. 라이브카지노 on

    I just could not depart your web site before suggesting that I really enjoyed the standard information a person provide for your visitors? Is going to be back often in order to check up on new posts

  52. โอลี่แฟน on

    Having read this I thought it was very informative. I appreciate you spending some time and effort to put this content together. I once again find myself personally spending way too much time both reading and commenting. But so what, it was still worthwhile!

  54. gamdom giriş on

    Wonderful blog! I found it while searching on Yahoo News. Do you have any tips on how to get listed in Yahoo News? I’ve been trying for a while but I never seem to get there! Appreciate it

  56. gamdom giriş on

    You actually make it seem really easy along with your presentation but I find this matter to be actually one thing that I believe I would never understand. It kind of feels too complex and very broad for me. I am having a look ahead to your subsequent put up, I?ll try to get the hold of it!

  67. kèo nhà cái on

    I really love your blog.. Very nice colors & theme. Did you create this amazing site yourself? Please reply back as I’m wanting to create my very own blog and want to learn where you got this from or what the theme is called. Thank you.

  71. home staging Narbonne on

    I have seen many useful issues on your website about personal computers. However, I have the judgment that notebook computers are still more or less not powerful adequately to be a sensible choice if you frequently do jobs that require a great deal of power, including video croping and editing. But for world wide web surfing, microsoft word processing, and most other popular computer work they are just fine, provided you do not mind the small screen size. Appreciate sharing your thinking.

  72. sportingpost.com on

    Hi there would you mind stating which blog platform you’re using? I’m going to start my own blog soon but I’m having a hard time selecting between BlogEngine/Wordpress/B2evolution and Drupal. The reason I ask is because your design seems different then most blogs and I’m looking for something unique. P.S My apologies for being off-topic but I had to ask!|

  74. architecte d'intérieur Narbonne on

    Nice post. I was checking constantly this blog and I’m inspired! Extremely helpful information particularly the closing section 🙂 I deal with such info a lot. I was looking for this certain information for a long time. Thank you and good luck.

  75. décoratrice Béziers on

    Hello, i think that i saw you visited my blog so i came to ?return the favor?.I’m attempting to find things to improve my website!I suppose its ok to use a few of your ideas!!

  77. décoratrice intérieur Béziers on

    Simply desire to say your article is as astonishing. The clearness in your post is just spectacular and i can assume you’re an expert on this subject. Well with your permission let me to grab your feed to keep updated with forthcoming post. Thanks a million and please keep up the enjoyable work.

  78. bicyclinginfo.org on

    Hi my family member! I want to say that this article is amazing, great written and come with almost all vital infos. I would like to peer more posts like this .|

  80. bicyclinginfo.org on

    Right now it seems like BlogEngine is the top blogging platform out there right now. (from what I’ve read) Is that what you’re using on your blog?|

  83. 18+ on

    Thanks for giving your ideas. I might also like to convey that video games have been actually evolving. Better technology and inventions have aided create reasonable and fun games. Most of these entertainment video games were not as sensible when the actual concept was first being attempted. Just like other styles of know-how, video games also have had to grow by means of many generations. This is testimony to the fast growth of video games.

  85. Porn on

    Hiya! Quick question that’s totally off topic. Do you know how to make your site mobile friendly? My web site looks weird when viewing from my iphone4. I’m trying to find a template or plugin that might be able to fix this problem. If you have any recommendations, please share. With thanks!

  86. Film Bokep on

    I was recommended this web site by my cousin. I am now not positive whether or not this put up is written through him as no one else recognize such distinct about my difficulty. You’re amazing! Thanks!

  87. Bokep on

    Thanks, I’ve been searching for details about this topic for ages and yours is the best I have discovered so far.

  90. crisis prevention intervention instructor training, on

    You really make it appear really easy with your presentation however I in finding this matter to be actually something which I believe I might by no means understand. It kind of feels too complicated and extremely extensive for me. I’m looking forward in your next submit, I?ll attempt to get the hold of it!

  91. cpi instructor training course, on

    We are a gaggle of volunteers and opening a brand new scheme in our community. Your site provided us with helpful information to paintings on. You’ve done an impressive task and our entire neighborhood might be thankful to you.

  93. click here on

    It’s really a great and helpful piece of info. I’m satisfied that you just shared this useful info with us. Please stay us up to date like this. Thank you for sharing.|

  94. sportingpost.com on

    If you are going for most excellent contents like myself, only pay a quick visit this web page all the time for the reason that it provides feature contents, thanks|

  95. french porn on

    Simply wish to say your article is as amazing. The clarity in your post is simply great and i could assume you are an expert on this subject. Well with your permission let me to grab your feed to keep updated with forthcoming post. Thanks a million and please keep up the gratifying work.

  97. Bokep on

    okmark your blog and check again here frequently. I’m quite certain I?ll learn many new stuff right here! Best of luck for the next!

  98. porn on

    I do not even know how I ended up here, but I thought this post was good. I don’t know who you are but certainly you’re going to a famous blogger if you are not already 😉 Cheers!

Leave A Reply